Literature DB >> 9176237

Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation.

A Uchida1, T Yamada, T Hayakawa, M Hoshino.   

Abstract

Intraluminal bacteria, food intake, and bile play important roles in indomethacin-induced small intestinal inflammation in rats. Tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) inhibit hydrophobic bile acid-induced damage in various types of cells. We investigated the effects of these bile acids along with the possible influence of other bile acids on this model of inflammation. Clinical and intestinal inflammatory parameters and bile secretion were assessed after 7-day dietary bile acid pretreatments and subsequent indomethacin injections. UDCA significantly enhanced indomethacin-associated reductions in food intake and body weight, increases in gross inflammatory scores and myeloperoxidase activity, and the shortening of small intestinal length. Taurochenodeoxycholic acid (TCDCA) significantly normalized the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation. Although elevated biliary levels of muricholic acids and a decreased hydrophobicity index were evident before indomethacin injection in the TCDCA case, these alterations could not explain the TCDCA-mediated protection. Dietary TCDCA attenuates whereas UDCA exacerbates intestinal inflammation in this model. Alterations in the bile composition (increases in UDCA and chenodeoxycholic acid) may explain the observed modification effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176237     DOI: 10.1152/ajpgi.1997.272.5.G1249

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  Beneficial effects of glycocholic acid (GCA) on gut mucosal damage in bile duct ligated rats.

Authors:  B K Oktar; M A Gülpinar; F Ercan; A Cingi; I Alican; B C Yegen
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

Review 2.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

3.  FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats.

Authors:  Hyder Said; Yasutada Akiba; Kazuyuki Narimatsu; Koji Maruta; Ayaka Kuri; Ken-Ichi Iwamoto; Atsukazu Kuwahara; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

4.  Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.

Authors:  Jamie M Golden; Oswaldo H Escobar; Michelle V L Nguyen; Michael U Mallicote; Patil Kavarian; Mark R Frey; Christopher P Gayer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-04-19       Impact factor: 4.052

5.  Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.

Authors:  Carlos Felipe Bernardes-Silva; Adérson O M C Damião; Aytan M Sipahi; Francisco R M Laurindo; Kiyoshi Iriya; Fabio P Lopasso; Carlos A Buchpiguel; Maria Laura L Lordello; Carmem L O Agostinho; Antonio A Laudanna
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

6.  Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats.

Authors:  M Barbier; C Cherbut; A C Aubé; H M Blottière; J P Galmiche
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

7.  Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model.

Authors:  Seung Han Kim; Hoon Jai Chun; Hyuk Soon Choi; Eun Sun Kim; Bora Keum; Yeon Seok Seo; Yoon Tae Jeen; Hong Sik Lee; Soon Ho Um; Chang Duck Kim
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

Review 8.  Crohn's disease: NOD2, autophagy and ER stress converge.

Authors:  Teresa Fritz; Lukas Niederreiter; Timon Adolph; Richard S Blumberg; Arthur Kaser
Journal:  Gut       Date:  2011-01-19       Impact factor: 23.059

Review 9.  Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Authors:  R K Boyapati; A G Rossi; J Satsangi; G-T Ho
Journal:  Mucosal Immunol       Date:  2016-03-02       Impact factor: 7.313

10.  The Nonsteroidal Anti-Inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids Without Inducing Intestinal Damage or Delaying Peristalsis in the Rat.

Authors:  Barbara Hutka; Bernadette Lázár; András S Tóth; Bence Ágg; Szilvia B László; Nóra Makra; Balázs Ligeti; Bálint Scheich; Kornél Király; Mahmoud Al-Khrasani; Dóra Szabó; Péter Ferdinandy; Klára Gyires; Zoltán S Zádori
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.